(ARKG) ARK Genomic Revolution - Overview
Etf: Genetic, Therapies, Sequencing, Diagnostics, Research
| Risk 5d forecast | |
|---|---|
| Volatility | 47.9% |
| Relative Tail Risk | -4.24% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -19.16 |
| Character TTM | |
|---|---|
| Beta | 1.505 |
| Beta Downside | 1.140 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.96% |
| CAGR/Max DD | -0.07 |
Description: ARKG ARK Genomic Revolution January 20, 2026
The ARK Genomic Revolution ETF (BATS: ARKG) is an actively-managed, non-diversified ETF that commits at least 80 % of its assets to domestic and foreign equities across healthcare, information technology, materials, energy, and consumer discretionary sectors, provided those companies are positioned to benefit from the “genomics revolution.”
As of early 2024, ARKG manages roughly $1.5 billion in assets with an expense ratio of 0.75 %, and its top holdings include CRISPR Therapeutics, Illumina, and Pacific Biosciences-companies directly involved in gene editing, sequencing, and synthetic biology. The global genomics market has been expanding at an estimated compound annual growth rate (CAGR) of 20 % and is projected to exceed $40 billion by 2027, driven primarily by falling DNA-sequencing costs (now under $100 per genome) and accelerating regulatory approvals for gene-therapy products.
For a deeper quantitative breakdown, the ValueRay platform offers granular metrics that can help you assess ARKG’s risk-adjusted performance.
What is the price of ARKG shares?
Over the past week, the price has changed by -5.39%, over one month by -8.60%, over three months by +1.52% and over the past year by +5.19%.
Is ARKG a buy, sell or hold?
What are the forecasts/targets for the ARKG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.3 | -1.6% |
ARKG Fundamental Data Overview February 05, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.41b USD (1.41b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.41b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.41b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 11.46% (E(1.41b)/V(1.41b) * Re(11.46%) + (debt-free company))
Discount Rate = 11.46% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)